• Molecular NameNaltrexone
  • Synonymnaltrexone; PTI-555
  • Weight341.407
  • Drugbank_IDDB00704
  • ACS_NO16590-41-3
  • Show 2D model
  • LogP (experiment)1.92
  • LogP (predicted, AB/LogP v2.0)1.61
  • pkaN/A
  • LogD (pH=7, predicted)0.33
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.22
  • LogSw (predicted, AB/LogsW2.0)0.68
  • Sw (mg/ml) (predicted, ACD/Labs)0.53
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds2
  • TPSA70.0
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
  • Absorption_value95.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability22.0
  • Protein binding20.0
  • Volume of distribution (VD)20 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. When administered orally, naltrexone undergoes extensive biotransformation and is metabolized to 6 beta-naltrexol (which may contribute to the therapeutic effect) and other minor metabolites.
  • Half life10 h for naltrexone and about 12 h for 6β-naltrexol; after intravenous administration, naltrexone about 3 h.
  • Excretionrenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50=1450 mg/kg
  • LD50 (mouse)LD50=1100~1550 mg/kg